One Choice, Multiple Wins: Semaglutide as First-Line Therapy in T2D – CME by Novo
Academic Participation
Dr. Sudhir Bhandari participated in CME by Novo on 30 June 2026, contributing to the programme as speaker / faculty. His session focused on One Choice, Multiple Wins: Semaglutide as First-Line Therapy in T2D, reflecting his continuing engagement in medical education, clinical dialogue and professional knowledge-sharing.
Dr Sudhir bhandari Dr Prakash keshwani 30 June 2026 Precision in Diabesity Practice Agenda
